[Clinical observation of CD19-TANK cells in the treatment of relapsed/refractory B-cell lymphoma].

Autor: Zhang XD; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Fu XR; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Sun ZC; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Zhang L; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Li X; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Li L; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Wu JJ; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Wang XH; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Nan FF; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Chang Y; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Yu H; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Li ZM; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China., Zhang MZ; Department of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Jazyk: čínština
Zdroj: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2022 Feb 14; Vol. 43 (2), pp. 153-156.
DOI: 10.3760/cma.j.issn.0253-2727.2022.02.012
Databáze: MEDLINE